• Satoshi Deyama, Eunyoung Bang, Eric S Wohleb, Xiao-Yuan Li, Taro Kato, Danielle M Gerhard, Sophie Dutheil, Jason M Dwyer, Seth R Taylor, Marina R Picciotto, and Ronald S Duman.
• Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. (Deyama, Bang, Wohleb, Li, Kato, Gerhard, Dutheil, Dwyer, Taylor, Picciotto, Duman); Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan (Deyama); Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati (Wohleb); Drug Development Research Laboratories, Sumitomo Dainippon Pharma, Suita, Japan (Kato).
• Am J Psychiatry. 2019 May 1; 176 (5): 388-400.

ObjectiveThe N-methyl-d-aspartate receptor antagonist ketamine produces rapid and sustained antidepressant actions even in patients with treatment-resistant depression. Vascular endothelial growth factor (VEGF) has been implicated in the effects of conventional monoamine-based antidepressants, but the role of VEGF in the rapid antidepressant actions of ketamine remains unclear. The authors examined whether neuronal VEGF signaling in the medial prefrontal cortex (mPFC) mediates the rapid antidepressant actions of ketamine.MethodsThe authors used a combination of approaches, including conditional, neuron-specific knockout of VEGF or its receptor, Flk-1; antibody neutralization; viral-mediated knockdown of Flk-1; and pharmacological inhibitors. Further in vitro and in vivo experiments were performed to examine whether neuronal VEGF signaling was required for the neurotrophic and synaptogenic actions of ketamine that underlie its behavioral actions.ResultsThe behavioral actions of systemic ketamine are blocked by forebrain excitatory neuron-specific deletion of either VEGF or Flk-1 or by intra-mPFC infusion of a VEGF neutralizing antibody. Moreover, intra-mPFC infusions of VEGF are sufficient to produce rapid ketamine-like behavioral actions, and these effects are blocked by neuron-specific Flk-1 deletion. The results also show that local knockdown of Flk-1 in mPFC excitatory neurons in adulthood blocks the behavioral effects of systemic ketamine. Moreover, inhibition of neuronal VEGF signaling blocks the neurotrophic and synaptogenic effects of ketamine.ConclusionsTogether, these findings indicate that neuronal VEGF-Flk-1 signaling in the mPFC plays an essential role in the antidepressant actions of ketamine.

32 keywords...

hide…